Skip to main content

Table 1 Baseline demographics of overall prostate cancer patients and comparison between TPL and non-TPL groups

From: The effect of subsequent immunosuppressant use in organ-transplanted patients on prostate cancer incidence: a retrospective analysis using the Korean National Health Insurance Database

Parameter Total TPL (N = 51,880) Non-TPL group (N = 38,910) TPL group (N = 12,970) p value
N (%) N (%) N (%)
Age (years; mean, STD) 48.10 (10.24) 48.1 ± 10.24 48.1 ± 10.24 1.000
Age, 20 ≤ Age < 50 25,856 (49.84) 19,392 (49.84) 6464 (49.84) 1.000
 50 ≤ Age < 65 24,308 (93.41) 18,231 (93.41) 6077 (93.41)  
 65 ≤ Age ≤ 75 1,688 (6.49) 1266 (6.49) 422 (6.49)  
 75 < Age 28 (0.11) 21 (0.11) 7 (0.11)  
Diagnostic Year of Prostate Cancer  < .001    
 2007–2009 1 (0.53) 0 (0) 1 (1.3)  
 2010–2012 40 (21.28) 20 (18.02) 20 (25.97)  
 2013–2015 147 (78.19) 91 (81.98) 56 (72.73)  
Year of transplanted surgery 1.000    
 2003–2007 12,524 (24.14) 9393 (24.14) 3131 (24.14)  
 2008–2012 18,532 (35.72) 13,899 (35.72) 4633 (35.72)  
 2013–2015 20,824 (40.14) 15,618 (40.14) 5206 (40.14)  
Underlying disease     
 Hypertension 15,511 (29.90) 7376 (18.96) 8135 (62.72) < .0001
 Diabetes 9,504 (18.32) 3253 (8.36) 6251 (48.2) < .0001
 Dyslipidemia 8,546 (16.47) 4461 (11.46) 4085 (31.5) < .0001
Medication     
 Aspirin 1776 (3.42) 803 (2.06) 973 (7.5) < .0001
 Statin 8701 (16.77) 4389 (11.28) 4312 (33.25) < .0001
 Use of Immunosuppressant agents 21,578 (41.59) 8623 (22.16) 12,955 (99.88) < .0001
 Duration of immunosuppressant, ≥ 300 days 11,338 (21.9) 225 (0.6%) 11,113 (85.68) < 0.001
Transplanted organ     
 1. Kidney 7,026 (13.54) N.A 7026 (54.17)  
 2. Liver 5,445 (10.50) N.A 5445 (41.98)  
 3. Pancreas 28 (0.05) N.A 28 (0.22)  
 4. Heart 398 (0.77) N.A 398 (3.07)  
 5. Lung 73 (0.14) N.A 73 (0.56)  
Charlson Comordity Index Grade 2  < 0.001    
 0 23,693 (45.67) 23,689 (60.88) 4 (0.03)  
 1 8,231 (15.87) 8126 (20.88) 105 (0.81)  
 2 or more 19,956 (38.47) 7095 (18.23) 12,861 (99.16)  
 Survival, alive 50,199 (96.61) 38,092 (97.90) 12,027 (92.73) < 0.001
 Survival time (year; mean SD) 4.86 (2.49) 4.9 ± 2.49 4.73 ± 2.49  
  1. N.A not available